Literature DB >> 9297732

Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.

J Zoer1, A M Schrander-van der Meer, W T van Dorp.   

Abstract

The standard dosage of vancomycin in haemodialysis patients is usually 1 gram, once a week. The aim of our study was to investigate vancomycin clearance by two highly permeable membranes and to determine whether dosage adjustment is necessary in regular haemodialysis settings when using these type of dialyzers. 12 patients on regular haemodialysis and treated with vancomycin either prophylactically or therapeutically were prospectively randomised to either dialysis with a polyacrylonitril parallel membrane (AN-69) or a cellulose-acetate hollow fiber membrane. After administering vancomycin to the patient vancomycin plasma levels were measured at different intervals. The vancomycin clearance by the dialyzer was calculated from blood samples taken 1 hour after commencing dialysis. The data were used for pharmacokinetic computer simulation in order to develop a vancomycin dosage regimen for patients on regular haemodialysis with highly permeable membranes. The mean vancomycin dialysis clearance was 46 +/- 5 ml/min and did not differ between the two artificial kidneys. Dialysis clearance of vancomycin was independent of blood flow rate. Together with the dialyzer data a pharmacokinetic profile of each patient was calculated from the plasma samples. The average non-renal clearance was 3.3 ml/min/1.73 m2 while renal vancomycin clearance, as a fraction of creatinine clearance, was found to be 0.83 +/- 0.20. The computer calculations predicted that, irrespective of residual renal function, in most patients on regular haemodialysis and treated with these type of artificial kidneys, therapeutic and non-toxic vancomycin levels could be obtained by giving 1000 mg of vancomycin intravenously as a loading dosage and 500 mg during every subsequent dialysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9297732     DOI: 10.1023/a:1008600104232

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  12 in total

1.  Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers.

Authors:  D M Lanese; P S Alfrey; B A Molitoris
Journal:  Kidney Int       Date:  1989-06       Impact factor: 10.612

2.  The in-vitro degradation at 37 degrees C of vancomycin in serum, CAPD fluid and phosphate-buffered saline.

Authors:  L O White; R Edwards; H A Holt; A M Lovering; R G Finch; D S Reeves
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790

3.  Hazards of rapid administration of vancomycin.

Authors:  P Newfield; M F Roizen
Journal:  Ann Intern Med       Date:  1979-10       Impact factor: 25.391

4.  Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes.

Authors:  J Böhler; P Reetze-Bonorden; E Keller; A Kramer; P J Schollmeyer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration.

Authors:  V De Bock; D Verbeelen; V Maes; J Sennesael
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

Review 6.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

7.  Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile.

Authors:  J Torras; C Cao; M C Rivas; M Cano; E Fernandez; J Montoliu
Journal:  Clin Nephrol       Date:  1991-07       Impact factor: 0.975

Review 8.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 9.  Vancomycin therapeutic drug monitoring: is it necessary?

Authors:  C D Freeman; R Quintiliani; C H Nightingale
Journal:  Ann Pharmacother       Date:  1993-05       Impact factor: 3.154

10.  Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure.

Authors:  C C Tan; H S Lee; T Y Ti; E J Lee
Journal:  Ther Drug Monit       Date:  1990-01       Impact factor: 3.681

View more
  5 in total

1.  Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis.

Authors:  Wasim S El Nekidy; Maher M El-Masri; Greg S Umstead; Michelle Dehoorne-Smith
Journal:  Can J Hosp Pharm       Date:  2016-10-31

2.  Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort study.

Authors:  Wasim S El Nekidy; Maher M El-Masri; Greg S Umstead; Michelle Dehoorne-Smith
Journal:  Can J Hosp Pharm       Date:  2012-11

3.  Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system.

Authors:  Soo Min Jang; Katie E Cardone; Thomas D Nolin; Darius L Mason; Darren W Grabe
Journal:  BMC Nephrol       Date:  2014-12-20       Impact factor: 2.388

4.  Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration.

Authors:  Erin Chung; James A Tjon; Rosaleen M Nemec; Nadya Nalli; Elizabeth A Harvey; Christoph Licht; Winnie Seto
Journal:  Kidney Int Rep       Date:  2021-02-06

Review 5.  Clinical review: use of vancomycin in haemodialysis patients.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Lucile Mercadal; Gilbert Deray
Journal:  Crit Care       Date:  2002-06-10       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.